The Death Panel Is About to Rule Death for Geraldine Satossky
by Robert Wenzel
Economic Policy Journal
Recently by Robert Wenzel: The Bizarre Connection Between the Son of an Original Gold Coin Dealer and the Ground Zero Mosque
The government should have never gotten into the healthcare business. Under the guise of providing healthcare for those who couldn't afford it, they have expanded the concept so that under ObamaCare we will all be forced to carry health insurance — and all suffer the consequences
What's worse is that the government will oversee what the health companies are required to cover and what they are not. For example, I'm sure that the young will be wildly overcharged relative to their risk, but there is no chance that if I decided to start a health insurance company to provide healthcare for youth and charge them a rate in line with their health risk that I would be allowed to do so.
""Universal" ObamaCare is a scam that will in part force youth to pay for the healthcare of the elderly. However, the structure of healthcare with rules being set at the macro level by Obama lieutenants will distort the market and result in bureaucratic pricing. We have all heard about the $300 toilet seats purchased by the military, wait until you hear the price that will be paid for Obama bed pans.
This bureaucratic pricing and budgeting will, of course, result in expenditures far beyond what has been projected and then the cuts in healthcare will come. Indeed, it is happening now with Medicare. The early Death Panels are in session. It is highly questionable that healthcare for the poor should be handled by government, but what should be under study now is what healthcare will look like under ObamaCare. Medicare is a good preview of what is likely to be ahead.
In today's WSJ, Geraldine Satossky describes what it is like coming up against the Death Panel:
I am 67 years young and I've been battling breast cancer for 11 years. I'm alive today because of a drug called Avastin. But by Friday the FDA is expected to revoke its approval of the drug for use against breast cancer. I'm terribly frightened — and angry.
My story begins in 1999, when I lifted my arm and discovered a web of popping red veins. Doctors identified a tumor, and I was diagnosed with breast cancer. Chemotherapy worked for a bit, but then the tumor started growing again. So I had a mastectomy.
In 2002, the cancer returned — this time to my liver. That meant my cancer had metastasized. It was treatable but no longer curable.
Once again I underwent surgery, a liver resection. I was then put on the drugs Navelbine and Etoposide. At first, it seemed to work — my cancer went into remission. But three years later, the cancer came back. I now had four tumors in my liver and my outlook wasn't very good. My doctor was blunt: "You're in big trouble," he told me.
Thankfully, a clinical trial had recently started and I was selected for a combination of Xeloda and Avastin. Xeloda is a chemotherapy pill that kills cancerous cells. Avastin cuts off blood-flow to tumors. Almost immediately two of my tumors disappeared. The duel-pronged approach appeared to be working.
September 17, 2010
©2010 Economic Policy Journal